Feline immunodeficiency virus (FIV) is a lentivirus that exhibits significant structural and pathological similarities to human immunodeficiency virus (HIV), establishing it as a valuable model for HIV vaccine development. In this study, artificial intelligence (AI) and immunoinformatics were employed to design a novel multi-epitope DNA vaccine targeting conserved regions of the FIV gag, pol, and env genes. Predicted B-cell and T-cell epitopes were evaluated for their capacity to induce strong immune responses while minimizing allergenic or toxic effects and were linked to the immune adjuvant PADRE. Structural analysis indicated that the vaccine construct is stable, soluble, and biocompatible, with a well-folded tertiary structure that binds Toll-like receptor 9 (TLR9) and elicits robust humoral and cellular immune responses. These findings identify a promising FIV vaccine candidate and provide insights for the development of next-generation HIV vaccines.
Feline immunodeficiency virus (FIV) is a lentivirus sharing significant structural and pathological similarities to human immunodeficiency virus (HIV), making it a valuable surrogate model for HIV vaccine design and development. Currently, there is no available effective vaccine could protect cats against FIV infection. This study aims to use some artificial intelligence and immunoinformatic to design a novel multi-epitope DNA vaccine targeting some conserved regions of FIV’s gag, pol, and env genes. The mapped B and T-cell epitopes across the key proteins of the FIV genomes were screened for their ability to trigger strong immune responses, while avoiding allergenic or toxic responses and were linked to the immune adjuvant PADRE. Analysis of the vaccine construct revealed a stable, soluble, and biocompatible vaccine construct with a well-folded tertiary structure capable of binding toll-like receptor 9 (TLR9) and eliciting a robust humoral and cellular immune response. These results demonstrate a promising FIV vaccine candidate with potential insight into future directions in next generation HIV vaccines. Further experimental validation is required to confirm the potential protective power of these putative vaccines in the protection of cats against FIV natural field infection.